GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Yearly HIV Injection Shows Promise in Prevention Efforts
A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is safe and has long-lasting effects for HIV prevention. While promising, the study's small sample size necessitates more research for broader conclusions.
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
News-Medical.Net on MSN2d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The Financial Express2d
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...